COMMUNIQUÉS West-GlobeNewswire

Oral Infigratinib Shows Meaningful Benefits Beyond Growth Within 52 Weeks in Children with Achondroplasia in the Phase 3 PROPEL 3 Trial
09/09/2026
- Treatment with oral infigratinib for 52 weeks in PROPEL 3 resulted in favorable trends against placebo in clinically meaningful exploratory endpoints including sleep apnea and otitis media events Stabilization of [...]
ViaNautis Bio welcomes SCI Ventures as new investor, expanding CNS portfolio into spinal cord injury
09/09/2026
Investment supports application of ViaNautis’ polyNaut ® platform to regenerative therapies for spinal cord injury, where targeted delivery remains a huge barrier Adds a new high-value CNS indication and provides [...]
Biocomposites to host industry symposium and present new STIMULAN® data at EBJIS-MSIS 2026
09/09/2026
Industry symposium to explore local delivery of combination antibiotics across spine and arthroplasty Poster showcases the efficacy of STIMULAN ® calcium sulfate beads, loaded with a combination of Gram-positive and [...]
Allegro’s Hydrocelin significantly improves knee osteoarthritis pain and function in clinical trial
09/09/2026
Nanotechnology-based injection significantly improved knee pain and function with favorable safety and efficacy sustained over 6 months following a single administration Feasibility trial in Belgium completed [...]
Pharming Group to participate in September investor conferences
09/09/2026
Leiden, the Netherlands, September 9, 2026: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) today announced that its management will participate in the following investor conferences in the [...]
GENFIT Highlights Long-Term Commercial Opportunity for its MASH Diagnostics Technology
09/09/2026
Simple, reliable and scalable blood-based testing could identify patients with at-risk MASH among nearly 90 million U.S. individuals receiving medical attention due to MASLD-related risk factors IQVIA estimates U.S peak [...]
GENFIT présente le potentiel commercial à long terme de sa technologie de diagnostic dans la MASH
09/09/2026
Un test sanguin simple, fiable et déployable à grande échelle permettrait d’identifier les patients atteints de MASH à risque parmi les près de 90 millions d’Américains bénéficiant d’un suivi médical en raison de [...]
ONWARD Medical Reports First Half 2026 Results with Strong Product Revenue Growth and Continued Progress across ARC Therapy Pipeline
09/09/2026
THIS PRESS RELEASE CONTAINS INSIDE INFORMATION WITHIN THE MEANING OF ARTICLE 7(1) OF THE EUROPEAN MARKET ABUSE REGULATION (596/2014) EINDHOVEN, the Netherlands, Sept. 09, 2026 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. ( [...]
InnoCare Announces Approval of Clinical Trial of Novel Bispecific ADC ICP-B381 Targeting PSMA/ STEAP1 in China
09/09/2026
BEIJING, Sept. 08, 2026 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 9969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the Center for [...]
ICG-21 Opens in Shenzhen, Spotlighting Bio-Generative Intelligence for Health and New Frontiers in Genomics
09/09/2026
SHENZHEN, China, Sept. 08, 2026 (GLOBE NEWSWIRE) -- The 21st Annual Meeting of the International Conference on Genomics (ICG-21) was held at the BGI Center in Shenzhen from September 7 to 8. Under the theme “Bio- [...]
XORTX Re-Engages Investor Relations Program
09/09/2026
CALGARY, Alberta, Sept. 08, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (" XORTX " or the “ Company ”) announces that, following completion of its previously announced voluntary delisting from the TSX Venture [...]
HealthEx Empowers Consumers to Bring Their Personal Health History to Muse, Meta’s New Personal AI Agent
08/09/2026
Americans can connect their health history to Muse using HealthEx and make progress on their health goals with a plan that adapts to their life as their clinical context changes SAN FRANCISCO, Sept. 08, 2026 (GLOBE [...]
Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
09/09/2026
CAMBRIDGE, Mass., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB) (“Seres” or the “Company”), a leading live biotherapeutics company, today announced that on September 4, 2026, the [...]
Daxor Corporation to Participate in the 10th Annual Lake Street Best Ideas Growth Conference
08/09/2026
Oak Ridge, TN, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, announces today that CEO and President Michael Feldschuh will participate in [...]
Inhibitor Therapeutics Highlights Key Developments and Reminds Stockholders of September 15 Annual Meeting
08/09/2026
TAMPA, Fla., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Inhibitor Therapeutics, Inc. (OTCQB: INTI) ("Inhibitor" or the "Company") today highlighted several important developments disclosed in its Quarterly Report on Form 10-Q [...]
CareMed Has Been Selected as a National Pharmacy Partner by BioCryst and Adds Orladeyo® (berotralstat) to Growing Rare Disease Portfolio
08/09/2026
NEW HYDE PARK, N.Y., Sept. 08, 2026 (GLOBE NEWSWIRE) -- CareMed, an independent specialty pharmacy, has been selected as a pharmacy partner by BioCryst Pharmaceuticals for Orladeyo ® (berotralstat), a plasma kallikrein [...]
Apnimed Reports Second Quarter 2026 Financial Results and Provides Corporate Update
08/09/2026
U.S. Food and Drug Administration (“FDA”) Accepted the NDA for AD109, with a proposed proprietary name Oxnimbi ™, and assigned a PDUFA target action date of February 28,   2027 If approved, Oxnimbi has the potential to [...]
ImageneBio to Participate in H.C. Wainwright 28th Annual Global Investment Conference in New York
08/09/2026
SAN DIEGO, Sept. 08, 2026 (GLOBE NEWSWIRE) -- ImageneBio, Inc. (Nasdaq: IMA) (“Imagene” or the “Company”) today announced that chief executive officer Kristin Yarema, Ph.D., will participate in a fireside chat at the H. [...]
InterCure Regains Compliance with Nasdaq Minimum Bid Price Requirement
08/09/2026
NEW YORK and HERZLIYA, Israel, Sept. 08, 2026 (GLOBE NEWSWIRE) -- InterCure Ltd. (Nasdaq: INCR) (TASE: INCR) (“InterCure” or the “Company”) announced today that it received written confirmation from the Listing [...]

Pages